Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising …

E Garin, L Lenoir, J Edeline, S Laffont… - European journal of …, 2013 - Springer
… predict response and survival in patients treated with glass microspheres. This method can
be … LTS enable fully personalized treatment planning with glass microspheres to be achieved. …

[HTML][HTML] Clinical and experimental study on regional administration of phosphorus 32 glass microspheres in treating hepatic carcinoma

L Liu, Z Jiang, GJ Teng, JZ Song… - World Journal of …, 1999 - ncbi.nlm.nih.gov
glass microsphere and evaluate its clinical significance. … patients with hepatic carcinoma,
including 79 cases of primary hepatic carcinoma and 14 cases of secondary hepati c carcinoma

… of macroaggregated albumin‐based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90Y‐loaded glass microsphere …

E Garin, Y Rolland, M Pracht, S Le Sourd… - Liver …, 2017 - Wiley Online Library
… We consecutively included 85 patients with hepatocellular carcinoma treated with 90 Y-loaded
glass microspheres. TD was calculated using a quantitative analysis of the MAA SPECT/…

[PDF][PDF] Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: Interim safety and survival data on 65 patients

BI Carr - Liver Transplantation, 2004 - Wiley Online Library
… 90Yttrium glass microspheres (Therasphere)1– 6 are described. … glass microspheres are
20 to 30 microns in diameter and made initially of silica containing 89Yttrium. The microspheres

… with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein …

E Garin, Y Rolland, J Edeline, N Icard… - Journal of Nuclear …, 2015 - Soc Nuclear Med
… hepatocellular carcinoma portal vein thrombosis (PVT) patients treated with 90 Y-loaded
glass microspheres using … Methods: The microspheres were administered to 41 hepatocellular …

Outcomes of radioembolization in the treatment of hepatocellular carcinoma with portal vein invasion: resin versus glass microspheres

DM Biederman, JJ Titano, NE Tabori… - Journal of vascular and …, 2016 - Elsevier
… with HCC and PVT, the outcomes in the present study in patients treated with 90 Y-glass
are comparable to the existing studies. The largest study by Salem et al (5) reported a median …

An experimental study and clinical pilot trials on yttrium‐90 glass microspheres through the hepatic artery for treatment of primary liver cancer

ZP Yan, G Lin, HY Zhao, YH Dong - Cancer, 1993 - Wiley Online Library
… We concluded that indications of 90-Y glass microspheres for treatment of patients with
PLC should be (1) vascular or hypervascular tumor, espwially with a distinct margin; (2) no …

Prognostic significance of neutrophil to lymphocyte ratio dynamics in patients with hepatocellular carcinoma treated with radioembolization using glass microspheres

X Li, SA Montazeri, R Paz-Fumagalli… - European Journal of …, 2021 - Springer
… radioembolization in most patients. All patients were treated with Yttrium-90 glass
microspheres, so our results may not apply to Yttrium-90 resin microspheres. The MIRD dosimetry …

… albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary …

E Garin, L Lenoir, Y Rolland, J Edeline… - Journal of Nuclear …, 2012 - Soc Nuclear Med
… in patients treated by 90 Y-loaded glass microspheres and … Methods: Thirty-six patients
with hepatocellular carcinoma (… treated with 90 Y-loaded glass microspheres. The T plan D …

Sustained safety and efficacy of extended-shelf-life 90Y glass microspheres: long-term follow-up in a 134-patient cohort

RJ Lewandowski, J Minocha, K Memon, A Riaz… - European journal of …, 2014 - Springer
… 2010, 134 patients underwent radioembolization with extended-shelf-life 90 Y glass
microspheres; data from 84 new patients were combined with data from our 50-patient pilot study …